Cel Sci Corporation (CVM)

[Dr. Johnny Fever]

Actually, there weren't "dozens" of subgroups in the trial. The 3/7th of the patients in the study who received MK + SOC were in two subgroups: those receiving chemo and radio post surgery, and those receiving only radiotherapy post surgery. Radiotherapy uses focused radiation to kill cancer cells and shrink tumors. However, chemotherapy introduces a drug (a toxin) to affect cancer cells. The drug [toxin] must ultimately be metabolized and processed by the body, and this can affect multiple areas, functions, and pathways in the body. It is entirely reasonable to see conclude that chemotherapy negates the benefits of MK. The trial results show that MK does have benefits, and is line with the recent revelations that the benefits of immunotherapy are actually greater over a longer timeframe than in a (relatively) short amount of time, and that specifically the patients receiving chemo didn't see a statistical benefit of MK is actually proof that it boosts the immune system. CVM has done something extraordinary here, and other companies will follow in their footsteps.

"But they never reported the overall data. And that is the key to understanding when companies spin subgroups."

So, the full data for the trial results wouldn't be released at this point, because that's not how it is done. The ultimate conclusions of the trial (as addresses the endpoints) is released first, while the company prepares the full data for public consumption (i.e. dumb it down for non-science types - the full data will be released in it's pure form to the scientific community). Today's PR is entirely in line with what GK said would be the company's MO regarding trial results all along. The company will release the full data later.